|Exclusion Criteria:||1) Burkitt's lymphoma, Lymphoblastic lymphoma, Chronic lymphocytic leukemia and cutaneous T-cell lymphoma|
2) Chemotherapy or radiation therapy or other investigational agents within 3 weeks prior to entering the study unless there is clear evidence of progression of disease and toxicity from previous treatment has resolved in which case study entry may be within 1 week of last treatment
3) Previous radioimmunotherapy within 12 weeks
4) Patients with known Human immunodeficiency virus (HIV) infection must not have CD4 cells <400/mm3 and who must not have a prior acquired immunodeficiency syndrome (AIDS)-defining diagnosis and can not be on antiretroviral therapy for HIV
5) Known active viral hepatitis
6) Any serious active disease or co-morbid condition, which in the opinion of the principle investigator, will interfere with the safety or with compliance with the study
7) Poor bone marrow reserve as defined by absolute neutrophil count < 1.5 x109/L or platelets < 75 x 109/L
8) Poor organ function as defined by one of the following: Total bilirubin > 1.5 x upper limit of normal (ULN) (>3 x ULN for patients with liver involvement) Aspartate transaminase (AST), Alanine transaminase (ALT) > 2.5 x ULN (> 5 x ULN for patients with liver involvement) Serum creatinine > 2 x ULN HbA1C>8%
9) Patients receiving any medications or substances that are inhibitors or inducers of CYP 450 3A4 are ineligible. Lists including medications and substances known or with the potential to interact with the CYP 450 3A4 isoenzymes.
10) Preclinical studies demonstrated the potential of MK-2206 for induction of hyperglycemia in all preclinical species tested. Patients with diabetes or in risk for hyperglycemia should not be excluded from trials with MK-2206, but the hyperglycemia should be well controlled on oral agents before the patient enters the trial.
11) Preclinical studies indicated transient changes in QTc interval during MK-2206 treatment. Prolongation of QTc interval is potentially a safety concern while on MK-2206 therapy. Cardiovascular: baseline QTcF > 450 msec (male) or QTcF >470 msec (female) will exclude patients from entry on study. A list of medications that may cause QTc interval prolongation are listed and should be avoided by patients entering on trial.
12) Significant heart block or baseline bradycardia <50bpm due to cardiac disease
13) Patients who are pregnant or breastfeeding